Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab
Silvia Camera(Vita-Salute San Raffaele University), Giovanni Farinea(University of Turin), Guido Giordano(University of Foggia), Monica Verrico(Policlinico Umberto I), Oluseyi Abidoye(Mayo Clinic), Emiliano Tamburini(Ospedale Infermi di Rimini), Anna Saborowski(Medizinische Hochschule Hannover), Alessandro Pastorino(Ospedale Policlinico San Martino), Fabian Finkelmeier(Goethe University Frankfurt), Alessandro Parisi(Marche Polytechnic University), Mara Persano(Vita-Salute San Raffaele University), Lukas Perkhofer(University Hospital Ulm), Lorenzo Fornaro(Azienda Ospedaliera Universitaria Pisana), Florian Castet(Institut d'Investigació Biomédica de Bellvitge), Ilario Giovanni Rapposelli(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Chiara Braconi(Beatson West of Scotland Cancer Centre), Marta Schirripa(Azienda Sanitaria Locale Viterbo), G. Prager(Medical University of Vienna), Anna Diana(University of Campania "Luigi Vanvitelli"), Jessica Lucchetti(Campus Bio Medico University Hospital), Jorge Adeva(Hospital Universitario 12 De Octubre), Nicola Personeni(IRCCS Humanitas Research Hospital), Maria Grazia Rodriquenz(Casa Sollievo della Sofferenza), Ester Oneda(Fondazione Poliambulanza Istituto Ospedaliero), Federico Rossari(Vita-Salute San Raffaele University), Salvatore Corallo(Fondazione IRCCS Istituto Nazionale dei Tumori), Chiara Gallio(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Ingrid Garajová(University of Parma), Aitzaz Qaisar, Spinelli Gp(Sapienza University of Rome), Frederik Peeters, Antonio Avallone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Jin Won Kim(Seoul National University Bundang Hospital), Margherita Rimini(Vita-Salute San Raffaele University), Silvana Assunta Leo(Ospedale Vito Fazzi), Il Hwan Kim(Inje University Haeundae Paik Hospital), Changhoon Yoo(Ulsan College), T. Satake(National Cancer Center Hospital East), Stephen Lam Chan(Chinese University of Hong Kong), S. Tamberi(Ospedale "Santa Maria delle Croci" di Ravenna), Francesca Salani(University of Pisa), Pircher Chiara(Fondazione IRCCS Istituto Nazionale dei Tumori), Lorenzo Antonuzzo(Azienda Ospedaliero-Universitaria Careggi), Mario Domenico Rizzato(Istituto Oncologico Veneto), Ricardo Roque(Instituto Português de Oncologia de Coimbra Francisco Gentil), Hong Jae Chon(CHA University Bundang Medical Center), Mario Scartozzi(University of Cagliari), C. Melo Alvim(Centro Hospitalar Lisboa Norte), Nuno Couto(Champalimaud Foundation), S. Bozzarelli(IRCCS Humanitas Research Hospital)
Cited by 1
Related Papers
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
|Science|2018|2.1k
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k